SCHEDULE: Catalyst4 Boosts MapLight Stake Post-IPO to 45.1%

Catalyst4, Inc. and its directors have reported a significant 45.1% beneficial ownership in MapLight Therapeutics, Inc. following its initial public offering and a concurrent private placement.

Summary

• Catalyst4, Inc. and its directors (Robert Brown, Ekemini Riley, Mark Vorsatz) collectively reported beneficial ownership of 19,697,464 shares of MapLight Therapeutics, Inc. common stock.
• This represents 45.1% of the total common stock outstanding and 48.1% of the voting common stock.
• The acquisition was for investment purposes, with Catalyst4 reserving the right to adjust its holdings based on market conditions and company performance.
• Prior to the IPO, Catalyst4 invested $294,045,616.33 in various series of preferred stock.
• On October 28, 2025, these preferred shares converted into 14,256,288 common shares.
• Concurrently, Catalyst4 purchased an additional 5,441,176 common shares in the IPO at $17.00 per share, totaling $92,499,992.
• The total shares outstanding after the IPO and concurrent private placement are 43,641,422, including 2,727,511 non-voting common stock.

Sentiment

Score: 7

Explanation: The filing indicates a substantial, long-term investment by Catalyst4, Inc. in MapLight Therapeutics, Inc., including significant pre-IPO funding and participation in the IPO. This demonstrates strong confidence in the company. However, the disclosure of potential future sales by Catalyst4 and the standard lock-up period introduce some uncertainty and potential future selling pressure.

Positives

• Catalyst4, a significant investor, has a substantial stake (45.1% of common stock, 48.1% of voting common stock) in MapLight Therapeutics, indicating strong conviction.
• The investment was made through both pre-IPO preferred stock conversions and a direct purchase in the IPO, demonstrating continued support for the company's public debut.
• The Investors' Rights Agreement provides Catalyst4 with demand and piggyback registration rights, offering liquidity options for its large holding.

Negatives

• Reporting Persons are subject to a 180-day lock-up agreement from October 26, 2025, restricting their ability to dispose of or hedge shares without underwriter consent.
• The filing indicates that Catalyst4 may decide to sell all or part of its investment in the future, which could create selling pressure.

Risks

• Catalyst4 may change its investment strategy and decide to sell all or part of its investment in MapLight Therapeutics, potentially impacting share price.
• The lock-up agreement restricts the ability of Catalyst4 and other pre-IPO holders to sell shares for 180 days, which could lead to increased selling pressure once the lock-up expires.

Future Outlook

Catalyst4 acquired MapLight Therapeutics' common stock for investment purposes and intends to continuously review its investment based on the Issuer's business, prospects, market conditions, and other opportunities. While there are no present plans for extraordinary corporate transactions, management changes, or changes in capitalization or dividend policy, Catalyst4 reserves the right to adopt such plans in the future.

Management Comments

• "The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13D."
• "Catalyst has acquired the Issuer's common stock owned by it for investment purposes."
• "Catalyst intends to review on a continuing basis various factors relating to its investment in the Issuer... Based on these factors, Catalyst may decide to change its current intention to purchase additional securities of the Issuer and may determine to sell all or part of its investment in the Issuer."

Industry Context

This filing indicates a significant institutional investment in a biotechnology/pharmaceutical company (MapLight Therapeutics, Inc.) following its IPO. Such substantial ownership by a single entity like Catalyst4 can signal confidence in the company's long-term prospects within the competitive biotech sector, especially given the prior preferred stock investments. The lock-up agreement is standard for IPOs in this industry, aiming to stabilize the stock post-listing.

Comparison to Industry Standards

• The 180-day lock-up period is a standard practice for IPOs in the biotechnology and broader capital markets, aligning with typical agreements seen with investment banks like Morgan Stanley, Jefferies, and Leerink Partners.
• The provision of demand and piggyback registration rights through an Investors' Rights Agreement is also a common feature for significant pre-IPO investors in growth companies, providing mechanisms for future liquidity that are comparable to those offered by other venture capital or institutional investors in similar-sized biotech IPOs.

Corporate Governance

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons have been a party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Related Party Transactions

• Catalyst4, Inc. (a reporting person) was a party to the Amended and Restated Investors' Rights Agreement with MapLight Therapeutics, Inc. (the Issuer) and other stockholders.
• Catalyst4, Inc. also entered into a Lock-up Agreement with the underwriters of the Issuer's IPO, along with the Issuer's directors and executive officers.

Stakeholder Impact

• Shareholders: The significant ownership by Catalyst4 (45.1%) could be seen as a vote of confidence, but the potential for future sales after the lock-up period expires could introduce volatility. The Investors' Rights Agreement provides a pathway for large shareholders to liquidate holdings.
• Management/Board: The filing explicitly states no present plans to change the Board of Directors or management, providing stability.
• Underwriters: The lock-up agreements are in place to protect the IPO's stability, benefiting the underwriters.

Next Steps

• Catalyst4 will continue to review its investment in MapLight Therapeutics, considering factors like business prospects, stock price, and market conditions.
• The 180-day lock-up period for Catalyst4 and other pre-IPO holders will expire around April 2026 (180 days from October 26, 2025).
• Catalyst4 may exercise its demand or piggyback registration rights under the Investors' Rights Agreement in the future to facilitate the sale of its shares.

Key Dates

Recommendation

The filing primarily details a significant ownership stake by Catalyst4, Inc. following MapLight Therapeutics' IPO. While the substantial investment and pre-IPO funding indicate confidence, the 180-day lock-up period means no immediate selling pressure from this large holder. However, the explicit statement that Catalyst4 may sell all or part of its investment in the future, combined with the eventual expiration of the lock-up, suggests potential future supply to the market. Without additional operational or financial performance data, a "hold" recommendation is prudent, acknowledging the institutional backing while recognizing future liquidity events.

Keywords

MapLight Therapeutics, Catalyst4, Schedule 13D, SEC filing, beneficial ownership, IPO, common stock, preferred stock conversion, lock-up agreement, investors' rights, biotechnology, pharmaceuticals